Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Onward Medical NVCHIX:ONWDB 38 Net Cash per Share is €0.69 as of Dec. 2025, which is 100% below its 10-year median of 6.50. GuruFocus rates CHIX:ONWDB with a GF Score™ of 38/100 and a GF Value™ of €361.93. The stock has 4 warning signs investors should review. Among 793 Biotechnology companies, Onward Medical NV ranks better than 65.07% on this metric.
Onward Medical NV (CHIX:ONWDb) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Onward Medical NV Net Cash per Share Related Terms
Onward Medical NV Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Onward Medical NV's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONWDB vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Onward Medical NV's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onward Medical NV Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Onward Medical NV's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Onward Medical NV's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Onward Medical NV's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onward Medical NV (CHIX:ONWDB) has a Net Cash per Share of €0.69 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Onward Medical NV and its competitors. This is 89% below median its historical median of 6.50. Over the past decade, Onward Medical NV's Net Cash per Share has ranged from 3.45 to 23.85. According to the industry distribution chart, Onward Medical NV ranks #277 out of 793 companies in the Biotechnology industry, placing it in the top 34.9%.
Is Onward Medical NV's Net Cash per Share too high?
Onward Medical NV's current Net Cash per Share of €0.69 is 89% below median its 10-year median of 6.50. Over the past 10 years, this metric has ranged from a low of 3.45 to a high of 23.85. Based on the distribution chart, Onward Medical NV ranks #277 out of 793 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Onward Medical NV has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Onward Medical NV's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Onward Medical NV ranks #277 out of 793 companies for Net Cash per Share. This puts Onward Medical NV in the upper half of its industry. The industry median Net Cash per Share is 5.11. Historically, Onward Medical NV's own Net Cash per Share has ranged from 3.45 to 23.85 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.11, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Onward Medical NV and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onward Medical NV's current Net Cash per Share is €0.69, which is 89% below median its own 10-year median of 6.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onward Medical NV stock overvalued right now?
Onward Medical NV (CHIX:ONWDB) has a current Net Cash per Share of €0.69. The stock's GF Value™ is €361.93, compared to a current price of €6.12 — trading 98.3% below its estimated fair value. The current Net Cash per Share is €0.69, which is 89% below median its 10-year median of 6.50. Onward Medical NV's overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Onward Medical NV (CHIX:ONWDB), the current Net Cash per Share is €0.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Onward Medical NV (CHIX:ONWDB) Overvalued in 2026?
Based on GuruFocus' analysis, Onward Medical NV stock appears to be undervalued.
The current stock price of €6.12 is trading 98.3% below its estimated GF Value™ of €361.93.
Key valuation signals for CHIX:ONWDB:
Net Cash per Share: €0.69 (89% below median its 10-year median of 6.50)
GF Value™: €361.93 vs. price of €6.12 (98.3% below fair value)
No single metric tells the full story. See the CHIX:ONWDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Onward Medical NV is developing and commercializing therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company's technology platforms are based on ONWARD ARC Therapy (ARC Therapy), targeted, programmed electrical stimulation of the spinal cord designed to restore movement, independence, and health in people with SCI.
38GF Score
Get the complete analysis for CHIX:ONWDB
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONWDB has been successfully added to your 
